Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REP 2139 in HBV Infected Patients
NCT02646189Phase 2Completed
- Sponsor
- Replicor Inc.
- Start
- Aug 2011
- Primary completion
- Aug 2013
- Modality
- Antisense DNA, Polymer-based Nanoparticles, Small Interfering RNA (siRNA)
- Countries
- 1
01
Overview
A Phase 2 trial of REP 2139-Mg in Chronic Hepatitis B (CHB), sponsored by Replicor Inc.. Started Aug 2011; status: completed.
02
Drugs
REP 2139-Mg
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT02646189.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02646189.